黄洪标
发布时间:2014-12-04  (浏览:)
    黄洪标,男,1980年6月出生,籍贯广东兴宁,广州医科大学病理生理学副教授,硕士生导师,广东省高校第八批“千百十工程”校级培养对象。现任广州市抗癌协会肿瘤复发与转移专业委员会委员。近年来共主持国家自然科学基金青年项目1项,面上项目1项, 省高校优秀青年创新人才培养计划1项,省优博论文资助项目1项,市科信局项目1项,校博士启动项目1项。3年来获得纵向科研经费100多万元。发表SCI论文15篇。代表作发表于Nature子刊Cell Res、Sci Rep,Cell子刊Cell Reports, Oncotarget, Int J Cancer,Cancer lett等国际知名杂志。学位论文入选2012年度广东省优秀博士论文。研究方向:泛素蛋白酶体系统与肿瘤。
    学习工作经历
2000,9-2005,6:广州中医药大学,获学士学位;
2005,9-2008,6:广州医学院病理生理学专业硕士研究生,获医学硕士学位;导师:刘金保教授;
2008,9-2011,6:广州医学院内科学专业博士研究生,获医学博士学位。导师:刘金保教授。
2011,7-2013,11:广州医学院基础学院病理生理学教研室讲师;
2013,12-至今:广州医科大学基础学院病理生理学教研室副教授;
    培养条件
目前招生方向为病理学与病理生理学方向,研究经费充足。本课题组依托广州医科大学蛋白质修饰与降解实验室,研究内容瞄准国际前沿科学;本课题组研究涉及基础医学、临床医学、药物化学、中西医结合、生物、化学等多个领域,是多学科研究生交汇的场所;目前与美国二家实验室建立了良好的合作关系,欢迎有志者加盟我们的团队。
    近年承担课题
1、国家自然科学基金青年项目:金诺芬抑制蛋白质降解在抗肿瘤治疗中的作用,23万,主持。
2、国家自然科学基金面上项目:去泛素化酶USP14调控前列腺癌生长的分子机制研究,70万,主持。
3、广东省高校优秀青年创新人才培养计划项目:左旋卡尼丁和蛋白酶体抑制剂硼替佐米协同抗肿瘤作用的实验研究,3万,主持。
4、广东省优秀博士论文资助项目:铜离子络合物(CuPT)新分子靶点确定及其在肝癌治疗中的作用,6万,主持。
5. 广州市科信局科研专项:去泛素化酶USP14在前列腺癌中的作用机制研究,20 万,主持。
    近期代表性论文
1. Huang H(黄洪标), Zhang X, Li S, Liu N, Lian W, McDowell E, Zhou P, Zhao C, Guo H, Zhang C,Yang C, Wen G, Dong X, Lu L, Ma N, Dong W, Dou QP, Wang X, Liu J.Physiological levels of ATP negatively regulate proteasome function.  Cell Res. 2010 Dec;20(12):1372-85.(第一作者, featured article,IF=9.41)
2. Huang H(黄洪标), Chen D, Li S, Li X, Liu N, Lu X, Liu S, Zhao K, Zhao C, Guo H, Yang C, Zhou P, Dong X, Zhang C, Guanmei, Dou QP, Liu J.Gambogic acid enhances proteasome inhibitor-induced anticancer activity.  Cancer Lett. 2011 Feb 28;301(2):221-8. (第一作者,IF=4.258)
3. Huang H(黄洪标), Liu N, Guo H, Liao S, Li X, Yang C, Liu S, Song W, Liu C, Guan L, Li B, Xu L, Zhang C, Wang X, Dou QP, Liu J.L-carnitine is an endogenous HDAC inhibitor selectively inhibiting cancer cell growth in vivo and in vitro.  PLoS One. 2012;7(11):e49062. (第一作者,IF=3.73)
4. Huang H(黄洪标), Liu N, Yang C, Liao S, Guo H, Zhao K, Li X, Liu S, Guan L, Liu C, Xu L, Zhang C, Song W, Li B, Tang P, Dou QP, Liu J.HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo.  PLoS One. 2012;7(12):e52576. (第一作者,IF=3.73)
5. Huang H(黄洪标), Hua X, Liu N, Li X, Liu S, Chen X, Zhao C, Lan X, Yang C, Dou QP, Liu J.Anacardic acid induces cell apoptosis associated with induction of ATF4-dependent endoplasmic reticulum stress.  Toxicol Lett. 2014 May 20;228(3):170-178. (第一作者,IF=3.355)
6. Huang H(黄洪标), Liu N, Zhao K, Zhu C, Lu X, Li S, Lian W, Zhou P, Dong X, Zhao C, Guo H, Zhang C, Yang C, Wen G, Lu L, Li X, Guan L, Liu C, Wang X, Dou QP, Liu J. Sanggenon C decreases tumor cell viability associated with proteasome inhibition.Front Biosci (Elite Ed). 2011 Jun 1;3:1315-25. (第一作者)
7. Liu N, Huang H(黄洪标), Xu L, Hua X, Li X, Liu S, Yang C, Zhao C, Zhao C, Li S, Dou QP, Liu J.The combination of proteasome inhibitors bortezomib and gambogic acid triggers synergistic cytotoxicity in vitro but not in vivo.  Toxicol Lett. 2014, 224(3): 333-40(并列第一,IF=3.355)
8. Liu N, Huang H(黄洪标), Liu S, Li X, Yang C, Dou QP, Liu J. Calcium channel blocker verapamil accelerates gambogic acid-induced cytotoxicity via enhancing proteasome inhibition and ROS generation.  Toxicol In Vitro. 2014, 28(3):419-25(并列第一,IF=3.207)
9. Liu N, Li X, Huang H(黄洪标), Zhao C, Liao S, Yang C, Liu S, Song W, Lu X, Lan X, Chen X, Yi S, Xu L, Jiang L, Zhao C, Dong X, Zhou P, Li S, Wang S, Shi X, Dou PQ, Wang X, Liu J.Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth . Oncotarget. 2014 Jun 18; 5(14):5453-71. (并列第一,IF=6.627).
10. Li X, Liu S, Huang H(黄洪标), Liu N, Zhao C, Liao S, Yang C, Liu Y, Zhao C, Li S, Lu X, Liu C, Guan L, Zhao K, Shi X, Song W, Zhou P, Dong X, Guo H, Wen G, Zhang C, Jiang L, Ma N, Li B, Wang S, Tan H, Wang X, Dou QP, Liu J. Gambogic acid is a tissue-specific proteasome inhibitor in vitro and in vivo.  Cell Rep. 2013 Jan 31;3(1):211-22. (并列第一,IF=7.207)
11. Yang H, Zhou P, Huang H(黄洪标), Chen D, Ma N, Cui QC, Shen S, Dong W, Zhang X, Lian W, Wang X, Dou QP, Liu J.Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo.  Int J Cancer. 2009 May 15;124(10):2450-9. (并列第一, ,IF=4.722)
12. Liu N, Liu C, Li X, Liao S, Song W, Yang C, Zhao C, Huang H(黄洪标), Guan L, Zhang P, Liu S, Hua X, Chen X, Zhou P, Lan X, Yi S, Wang S, Wang X, Dou QP, Liu J.A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases. Sci Rep. 2014 Jun 10;4:5240.(并列第一,IF=5.078)
13. Shi X, Chen X, Li X, Lan X, Zhao C, Liu S, Huang H(黄洪标), Liu N, Liao S, Song W, Zhou P, Wang S, Xu L, Wang X, Dou QP, Liu J.Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation.  Clin Cancer Res. 2014, 20 (1): 151-63(IF=8.193)
14. Liu S, Zhao C, Yang C, Li X, Huang H (黄洪标), Liu N, Li S, Wang X, Liu J.Gambogic acid suppresses pressure overload cardiac hypertrophy in rats.  Am J Cardiovasc Dis. 2013,3(4): 227-38
15. Li S, Li X, Guo H, Liu S, Huang H(黄洪标), Liu N, Yang C, Tang P, Liu J.Intracellular ATP Concentration Contributes to the Cytotoxic and Cytoprotective Effects of Adenosine.  PLoS One. 2013 Oct 3;8(10):e76731. (IF=3.5)
16. Zhao C, Liu S, Yang C, Li X, Huang H(黄洪标), Liu N, Li S, Wang X, Liu J.Gambogic acid moderates cardiac responses to chronic hypoxia likely by acting on the proteasome and NF-κB pathway. Am J Cardiovasc Dis. 2013 Aug 16;3(3):135-45.
17. Lu L, Qin A, Huang H(黄洪标), Zhou P, Zhang C, Liu N, Li S, Wen G, Zhang C, Dong W, Wang X, Dou QP, Liu J.Shikonin extracted from medicinal Chinese herbs exerts anti-inflammatory effect via proteasome inhibition.  Eur J Pharmacol. 2011 May 11;658(2-3):242-7.(IF=2.592)
18. Chen X, Shi X, Zhao C, Li X, Lan X, Liu S, Huang H(黄洪标), Liu N, Liao S, Zang D, Song W, Liu Q, Carter BZ, Dou QP, Wang X, Liu J.Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanisms.  Oncotarget. 2014 Aug 22. [Epub ahead of print] (IF=6.627)
    电子邮箱地址:hhb800616@126.com

 
 

©1958- 广州医科大学

技术支持:信息与现代教育技术中心

地址:广州市番禺区新造镇  电话:020-37103094  邮编:511436